ABEONA THERAPEUTICS INC. — Form 10-Q

Abeona Therapeutics executed an exclusive worldwide license agreement with Stanford University (effective August 3, 2016) for patent rights to gene therapy for recessive dystrophic epidermolysis bullosa. The agreement covers U.S. patent application Serial No. 62/274,700 and foreign equivalents. Abeona must pay a non-creditable issue royalty (amount redacted), annual maintenance fees (amounts redacted), milestone payments upon regulatory and commercial achievements (amounts redacted), and earned royalties on net sales (rate redacted, with floor rates if third-party royalties are paid). Abeona may sublicense with diligence requirements; Stanford receives a share of sublicensing income. A Change of Control fee applies if Abeona is acquired (amount redacted). The license survives the later of patent expiration or 10 years after first commercial sale.